Analysis of Inflammatory Factors Levels and Safety in the Treatment of Psoriasis with Apremilast

To analyze the levels of inflammatory factor and safety in treating psoriasis with apremilast, we selected 200 cases of psoriasis patients under-treated in our hospital from January 2021 to January 2022, divided them into control group and experimental group at random, 100 cases, respectively. Control group received normal treatment, while treated experimental group with apremilast. Compare both groups on the levels of inflammatory factors, psoriasis skin lesions and adverse drug reactions. Before treatment, both groups had no statistical difference on serum inflammatory factor levels, but they improved after treatment. Experimental group had more obvious improvement after treatment; it had higher interleukin-10 level than control group, but it possessed lower tumour necrosis factor alpha, interferon gamma, interleukin-23, interleukin-7 and interleukin-6 levels than control group (p<0.05). The psoriasis area and severity index score of both groups decreased after 4 w treatment and at the end of treatment compared before treatment, but experimental group possessed lower psoriasis area and severity index score after treatment than control group (p<0.05). The adverse drug reactions rate was 7.00 % in control group and 11.00 % in experimental group, the difference possessed no statistical significance (p>0.05). There was a certain efficacy and safety in treating psoriasis by apremilast, which can inhibit inflammatory factors level and improve the condition of skin lesions effectively. It is worth popularizing.